Drug Trial Radar · NCT04230499
Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 18, 2021
Primary completion
Dec 11, 2024
Study completion May 22, 2025
Sponsor
- Lead sponsor
- Rapamycin Holdings Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Cancer Insight, LLC; Biodexa Pharmaceuticals
- First posted
- Jan 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.
Conditions
- Familial Adenomatous Polyposis
Interventions
Encapsulated Rapamycin (eRapa)Drug
eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Colorectal Polyp Burden at Month 6Time frame: 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Michigan Medicine
Ann Arbor, Michigan
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
UT Health
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.